Expert Involvement in Scientific Advice

“The external panel of experts was top-notch. They gave exceptional insights that added real value to our market access plans.”

-    Market Access Manager, Canadian Affiliate of  Global Pharma Company

The Scientific Advice program includes an expert panel as part of the process for developing Scientific Advice. One or 2 clinical experts and one drug expert committee expert will be engaged for each Scientific Advice application. Experts will be selected based on their expertise in a particular therapeutic area relevant to the application, or their past experience in considering drugs for reimbursement through drug expert committees at Canada’s Drug Agency (CDA-AMC). In-house health economics experts also participate in the process. Alternate or additional experts in methodological areas relevant to the application may be consulted or considered for full participation, as required.

Experts engaged in the Scientific Advice program participate in 3 preparatory meetings with CDA-AMC staff and participate in the Scientific Advice meeting. They may provide their own opinions and perspectives however the final advice report is from the perspective of CDA-AMC.

External experts involved in the Scientific Advice program are required to sign a Nondisclosure Agreement and to comply with the Confidentiality Guidelines for Scientific Advice and the Conflict of Interest Guidelines for Contractors.

Read more about confidentiality or conflicts of interest for the Scientific Advice program.